Our aim is simple: to position ourselves upstream of the diagnosis and to propose innovative treatments to patients

A therapeutic revolution is happening.

MI both accelerates research and development in immuno-oncology and offers cancer patients more options in terms of diagnostics and treatments, as well as more innovative clinical trials.

MI today is a great accomplishment as it brings together for the first time all the expertise in immunology but it is above a new strategic step for all Marseille immunology players

As such, we are involved in the Marseille immunology biotope

Marseille Immunopole is born from the will of all partners to do even better and progress faster, and thus allow patients always to keep one step ahead of the disease.

“Projects like PIONeeR allow us to contribute to the understanding of resistance to immunotherapy while opening clinical research to patients in Corsica, who, until recently, had no choice other than to fly to Marseille or Paris for such opportunities.”

By creating this super innovation centre "outside the walls", which is Marseille Immunopole, we leverage our capabilities to ensure better and faster innovation.

The thrust of MI is the ability of Marseille researchers, clinicians and industrials to play as a team.

For many years our service at the Timone Hospital has collaborated with researchers including the " Natural Killer Cells and Innate Immunity" team of Eric VIVIER .

Veracyte (formerly HaliodDx) is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.

Today Marseille Immunopôle is a great opportunity to challenge our discipline with novel perspectives.

Diagnostic in immuno-oncology is an innovative field combining the latest discoveries in immunology and new imaging technologies, such as digital pathology.

Being primarily centred on the patient, my work combines the short-term management of the disease and the long-term of clinical research.